9342-8530 Quebec Inc DGCRF

Agreement/FDA trial

[ready2go1]

The Gen-Probe/Diagnocure agreement was the spark to get us back to $2 but we had a seller prior to that, who took advantage of the increase volume to unload shares. I had expected us to hit that price target and than settle around the $1.75 range before we begin a nice upward trend. (share price hit $1.40 and was sitting around 1.25 only to drop with the news of the offering) Everyone has been waiting for the FDA trial and now it is here.
     Gen-Probe sells their tests to bloodbanks who do not have sales reps that market and sell the tests. Thats why the acquisition was so important for both HPV and PCA3 in Europe. You will see Gen-Probe make another acquisition here in the States as FDA approval gets closer because they understand that you not only need the studies published in respected journals but you need the sales reps selling and marketing these new tests. Diagnocure will also partner up with a company to market/sell GCC. They were planning to use the money from the offering to build a sales team. GCC has the study, now all they need are the feet on the ground marketing and selling the test. The new blood test will help out alot but 2 reps just won't get it done. This will be the standard of care but for now, PCA3 is right where we want it and as I have said before it will bring in a large amount of rev in for gpro and diagnocure will see a % of that. PCA3 alone will take CUR to a market cap of +200mil.
(I also feel that there is money on the sidelines that wanted to get in on the offering and they will invest at some point)